Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $0.2213 (-2.12%) ($0.2213 - $0.2213) on Fri. Mar. 11, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.11% (three month average) | RSI | 65 | Latest Price | $0.2213(-2.12%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | TNXP advances 11.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) ACES(51%) EWY(51%) DRIV(47%) BOTZ(46%) IBB(45%) | Factors Impacting TNXP price | TNXP will decline at least -3.555% in a week (0% probabilities). VIXM(-53%) VXX(-41%) UUP(-23%) UNG(-19%) BNDX(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.555% (StdDev 7.11%) | Hourly BBV | 0.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $0.22(0.59%) | 10 Day Moving Average | $0.21(5.38%) | 20 Day Moving Average | $0.2(10.65%) | To recent high | -48.9% | To recent low | 29.7% | Market Cap | $59m | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |